Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + GemOx vs R-GemOx in R/R DLBCL
NCT04408638Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2021
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Feb 2021; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04408638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408638.